Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent

Clinical trials of immuno-chemotherapy were conducted on malignant lymphoma patients. Patients during the period from 1972 through 1977 were allocated to two groups retrospectively according to the mode of treatment, i.e., chemotherapy alone (historical control group, 35 patients) and chemotherapy with OK-432 (treated group, 15 patients). Comparisons were made of the two groups, which were homogeneous with regard to induction chemotherapy, maintenance chemotherapy, stage and histologic type of disease. The treated group had a higher remission rate, and a longer remission duration and survival than the control groups, especially in patients with Hodgkin's disease but the difference was not statistically significant owing to the limited number of cases.</p

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Monocytes in patients with malignant diseases Part 2

Absolute peripheral blood monocyte counts and the β-galactosidase activity of monocytes were studied in 60 patients with lung cancer, 20 with malignant lymphoma, 17 with other malignant diseases, 13 with sarcoidosis and 28 normal individuals. The monocyte count was 296.3±176.8/cmm in lung cancer, 315.6±160.0/cmm in malignant lymphoma, 217.8±89.6/cmm in sarcoidosis, and 298.6±144.1/cmm in normal individuals. Although there was no significant differences in the monocyte count of malignant and non-malignant diseases, all patients with lung cancer or malignant lymphoma had monocyte counts less than 100/cmm. In patients with lung cancer and malignant lymphoma, there was no significant differences in histological types or clinical stages. The monocyte count in lung cancer patients treated with streptococcal agent OK-432 was elevated to 484.9±269.0/cmm, as compared with 315.5±107.7/cmm before administration. A nadir of monocyte counts was found at one week after combination chemotherapy but recovery to normal value was observed by 3 weeks after. On the other hand, white blood cell counts reached a nadir 2 weeks after chemotherapy and recovered by 4 weeks after. The percentages of β-galactosidase positive monocytes were 21.5±11.5% in patients with lung cancer, 20.1±7.5% in malignant lymphomas, 19.1±6.8% in other malignant diseases and 25.3±12.4% in normal individuals. There was no significant differences in β-galactosidase activity related to histological types or clinical stages of patients with lung cancer and malignant lymphoma. No changes in β-galactosidase activity were found between before and after combination chemotherapy

Isolation of monocytes in human peripheral blood Part 1 by discontinuous density gradient

The isolation of monocytes in human peripheral blood by discontinuous density gradients was studied. Discontinuous density gradients were obtained by successive layering of bovine serum albumins into three layers in 10ml glass tubes. Buffy coat cells were layered on top of a gradient and centrifuged under various conditions of centrifugation. Optimal isolation was achieved by centrifugation on a three layer of 35-32-28% bovine serum albumin at 490g for 60 minutes. The purity, yield and recovery of monocytes at the interface between 35% and 32% bovine serum albumin were 54.0%, 7.0×10(5) and 22.0% respectively. After centrifugation on Conray-Ficoll mixtures, the interface fraction containing lymphocytes was removed and the bottom fraction containing monocytes and other cells was centrifuged under various condition. The optimal condition was on a three layer of 35-32-28% bovine serum albumin at 400g for 40 minutes. The purity of monocytes by this method increased to 75% but the yield and recovery declined to 2.5×10(5) and 4.5% respectively. From these data I concluded that isolation of monocytes from blood only on density gradients was difficult because of a partial overlap between monocytes and lymphocytes in the density distribution profiles

Measurements of ttˉt\bar{t} differential cross-sections of highly boosted top quarks decaying to all-hadronic final states in pppp collisions at s=13 \sqrt{s}=13\, TeV using the ATLAS detector

Measurements are made of differential cross-sections of highly boosted pair-produced top quarks as a function of top-quark and $t\bar{t}$ system kinematic observables using proton--proton collisions at a center-of-mass energy of $\sqrt{s} = 13$ TeV. The data set corresponds to an integrated luminosity of $36.1$ fb$^{-1}$, recorded in 2015 and 2016 with the ATLAS detector at the CERN Large Hadron Collider. Events with two large-radius jets in the final state, one with transverse momentum $p_{\rm T} > 500$ GeV and a second with $p_{\rm T}>350$ GeV, are used for the measurement. The top-quark candidates are separated from the multijet background using jet substructure information and association with a $b$-tagged jet. The measured spectra are corrected for detector effects to a particle-level fiducial phase space and a parton-level limited phase space, and are compared to several Monte Carlo simulations by means of calculated $\chi^2$ values. The cross-section for $t\bar{t}$ production in the fiducial phase-space region is $292 \pm 7 \ \rm{(stat)} \pm 76 \rm{(syst)}$ fb, to be compared to the theoretical prediction of $384 \pm 36$ fb

Measurements of ttˉt\bar{t} differential cross-sections of highly boosted top quarks decaying to all-hadronic final states in pppp collisions at s=13 \sqrt{s}=13\, TeV using the ATLAS detector

Measurements are made of differential cross-sections of highly boosted pair-produced top quarks as a function of top-quark and $t\bar{t}$ system kinematic observables using proton--proton collisions at a center-of-mass energy of $\sqrt{s} = 13$ TeV. The data set corresponds to an integrated luminosity of $36.1$ fb$^{-1}$, recorded in 2015 and 2016 with the ATLAS detector at the CERN Large Hadron Collider. Events with two large-radius jets in the final state, one with transverse momentum $p_{\rm T} > 500$ GeV and a second with $p_{\rm T}>350$ GeV, are used for the measurement. The top-quark candidates are separated from the multijet background using jet substructure information and association with a $b$-tagged jet. The measured spectra are corrected for detector effects to a particle-level fiducial phase space and a parton-level limited phase space, and are compared to several Monte Carlo simulations by means of calculated $\chi^2$ values. The cross-section for $t\bar{t}$ production in the fiducial phase-space region is $292 \pm 7 \ \rm{(stat)} \pm 76 \rm{(syst)}$ fb, to be compared to the theoretical prediction of $384 \pm 36$ fb